Top Markets
#1 Siren Siren +44.16%
#2 Seeker Seeker +24.16%
#3 Full Moon Full Moon +19.19%
#4 Zora Zora +17.31%
#5 Wrapped NXM Wrapped NXM +12.17%
#6 VVS Finance VVS Finance +10.65%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.49%
#8 Cryptopia Cryptopia +9.12%
#9 Axelar Axelar +8.99%
#10 0G 0G +7.80%
Coin of the day
Siren Siren
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
AgomAb Therapeutics N.V. American Depositary Shares AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. American Depositary Shares

AGMB
Kedudukan dalam Saham #11832
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company... AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Harga Saham
$13.26
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$653.15M
Perubahan (1 hari)
-4.17%
Perubahan (1 tahun)
-
Negara
BE
Perdagangan AgomAb Therapeutics N.V. American Depositary Shares (AGMB)

Kategori

Healthcare
Nisbah P/E bagi AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini AgomAb Therapeutics N.V. American Depositary Shares, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi AgomAb Therapeutics N.V. American Depositary Shares dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.